Related references
Note: Only part of the references are listed.Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers
Taweegrit Siripongboonsitti et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2023)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face
Cagri Turan et al.
JOURNAL OF COSMETIC DERMATOLOGY (2022)
Role of favipiravir in the treatment of COVID-19
Shashank Joshi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
Mohd Imran et al.
MOLECULES (2021)
Early clinical experience with imatinib in COVID-19: Searching for a dual effect
Alejandro Morales-Ortega et al.
JOURNAL OF INFECTION (2021)
Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma
Safa M. Megahed et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2021)
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Kyle Rosenke et al.
NATURE COMMUNICATIONS (2021)
Fluorescence of ocular surface in a Covid-19 patient after Favipiravir treatment: a case report
Mehmet Ali Doran et al.
VIROLOGY JOURNAL (2021)
Favipiravir and COVID-19: A Simplified Summary
Morteza Ghasemnejad-Berenji et al.
DRUG RESEARCH (2021)
Study of the binding affinity between imatinib and α-1 glycoprotein using nuclear spin relaxation and isothermal titration calorimetry
Mihaela Mic et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Understanding the interaction between α-1-acid glycoprotein (AGP) and potential Cu/Zn metallo-drugs of benzimidazole derived organic motifs: A multi-spectroscopic and molecular docking study
Mohamed F. AlAjmi et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2020)
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
Du Yin-Xiao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
COVID-19: Immunology and treatment options
Susanna Felsenstein et al.
CLINICAL IMMUNOLOGY (2020)
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
Massimo Breccia et al.
LEUKEMIA (2020)
Favipiravir tautomerism: a theoretical insight
Liudmil Antonov
THEORETICAL CHEMISTRY ACCOUNTS (2020)
The immunology of COVID-19: is immune modulation an option for treatment?
Jixin Zhong et al.
LANCET RHEUMATOLOGY (2020)
Evaluation of blood-brain barrier penetration and examination of binding to human serum albumin of 7-O-arylpiperazinylcoumarins as potential antipsychotic agents
Teresa Zolek et al.
BIOORGANIC CHEMISTRY (2019)
Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study
Orsolya Domotor et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2019)
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs
Nicholas Ingram et al.
AAPS JOURNAL (2019)
Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein
Sherri A. Smith et al.
PHARMACEUTICAL RESEARCH (2019)
An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions
Michel Bteich
HELIYON (2019)
Human carboxylesterases: a comprehensive review
Dandan Wang et al.
ACTA PHARMACEUTICA SINICA B (2018)
Serum Albumin Binding and Esterase Activity: Mechanistic Interactions with Organophosphates
Nikolay V. Goncharov et al.
MOLECULES (2017)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
Dose regimen of favipiravir for Ebola virus disease
France Mentre et al.
LANCET INFECTIOUS DISEASES (2015)
Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins
Eva A. Enyedy et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2015)
Imatinib binding to human serum albumin modulates heme association and reactivity
Elena Di Muzio et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity
Orsolya Doemoetoer et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2014)
Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib
Svenja Beckmann et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2014)
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies
Orsolya Doemoetoer et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2013)
Subdomain IB Is the Third Major Drug Binding Region of Human Serum Albumin: Toward the Three-Sites Model
Ferenc Zsila
MOLECULAR PHARMACEUTICS (2013)
Optical, Structural and Thermodynamic Studies of the Association of an Anti-leucamic Drug Imatinib Mesylate with Transport Protein
Ashwini H. Hegde et al.
JOURNAL OF FLUORESCENCE (2012)
Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands
Eva A. Enyedy et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
High-Throughput 1,536-Well Fluorescence Polarization Assays for α1-Acid Glycoprotein and Human Serum Albumin Binding
Adam Yasgar et al.
PLOS ONE (2012)
Acute-phase proteins: As diagnostic tool
Sachin Jain et al.
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES (2011)
The drug binding site of human α1-acid glycoprotein:: Insight from induced circular dichroism and electronic absorption spectra
Ferenc Zsila et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Selective binding of imatinib to the genetic variants of human α1-acid glycoprotein
Ilona Fitos et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2006)
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
Catherine Delbaldo et al.
CLINICAL CANCER RESEARCH (2006)
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma
B Li et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Acid-base profiling of imatinib (Gleevec) and its fragments
Z Szakács et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia
O Kretz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo
J Larghero et al.
BIOCHEMICAL PHARMACOLOGY (2003)
α1-Acid glycoprotein:: an acute phase protein with inflammatory and immunomodulating properties
T Hochepied et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571
HG Jorgensen et al.
BLOOD (2002)
Trimethyltin(IV) complexes with some selected DNA constituents
MMA Mohamed et al.
JOURNAL OF COORDINATION CHEMISTRY (2001)
Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
C Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
